微创肝切除治疗肝门部与肝内胆管癌:比较性研究的系统综述与荟萃分析
该系统综述与荟萃分析纳入37项非随机比较研究共4863例患者,比较微创与开腹肝切除治疗肝门部及肝内胆管癌的安全性及疗效。结果显示微创组主要并发症、死亡率及住院时间均降低,倾向性评分匹配队列中R0切除率及3年无病生存率更高,胆漏发生率相似。
要点
- 微创肝切除治疗肝门部及肝内胆管癌的主要并发症(13.3% vs 18.8%)和死亡率(3.0% vs 4.5%)低于开腹手术。
- 微创组住院时间更短(8.0 vs 10.9天),倾向性评分匹配队列中R0切除率更高(90.4% vs 81.4%)。
- 微创组3年无病生存率更优(49.9% vs 38.5%),胆漏发生率与开腹组相似(10.6% vs 11.7%)。
核心结论
- 微创肝切除治疗肝门部及肝内胆管癌可能具有与开腹手术相似的安全性,并在患者恢复和肿瘤学结局方面存在获益。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Cochrane数据库,纳入比较至少5例微创与开腹肝切除治疗肝门部或肝内胆管癌的原始研究。
- 共纳入37项非随机比较研究、4863例患者,其中肝门部胆管癌占24%、肝内胆管癌占76%;21项研究进行了倾向性评分匹配。
- 分析的手术方式包括腹腔镜2106例、机器人75例、开腹2662例。
主要发现
- 微创组主要并发症发生率为13.3%,开腹组为18.8%(OR 0.75,95%CI 0.62-0.90)。
- 微创组死亡率为3.0%,开腹组为4.5%(OR 0.69,95%CI 0.49-0.97)。
- 微创组住院时间为8.0天,开腹组为10.9天(MD -2.1,95%CI -2.8至-1.5)。
- 倾向性评分匹配队列中,微创组R0切除率为90.4%,开腹组为81.4%(OR 1.40,95%CI 1.13-1.74)。
- 微创组3年无病生存率为49.9%,开腹组为38.5%(HR3-year 3.2,95%CI 3.1-3.3)。
关键数值与推荐
- 中转率中位数为11.5%(IQR 10.0-12.5)。
- 在1180例接受肝管空肠吻合术的患者亚组中(腹腔镜498例、机器人65例、开腹617例),微创组主要并发症为20.9% vs 27.6%(OR 0.88,95%CI 0.64-1.21),死亡率为4.2% vs 4.9%(OR 0.51,95%CI 0.30-0.86)。
- 总体胆漏发生率为10.6% vs 11.7%(OR 0.83,95%CI 0.52-0.77)。
临床怎么用
- 对于肝门部及肝内胆管癌,微创肝切除可作为开腹手术的潜在替代方案,可能降低主要并发症和死亡率并缩短住院时间。
- 在需行肝管空肠吻合术的患者中,微创入路仍与死亡率降低相关,但需注意主要并发症的获益证据强度有限。
- 开展微创肝切除治疗胆管癌时应关注中转率(中位数11.5%),并由经验丰富的中心实施。
局限性
- 纳入研究均为非随机比较研究,存在选择偏倚等混杂因素。
- 机器人微创肝切除的病例数较少(75例),相关证据有限。
- 需要前瞻性比较研究(尤其包含机器人微创肝切除)进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The implementation of minimally invasive liver surgery (MILS) for perihilar (PHC) and intrahepatic cholangiocarcinoma (IHC) remains limited and a systematic review including only comparative studies of MILS versus the open approach is lacking. This systematic review and meta-analysis aimed to assess the safety and efficacy of minimally invasive surgery in patients with hilar and intrahepatic cholangiocarcinomas. METHODS: Systematic review in the PubMed, Embase, and Cochrane databases for original studies comparing at least five patients undergoing MILS with open liver surgery for PHC and IHC. Meta-analysis included the primary outcomes of morbidity and mortality. Secondary outcomes included post-operative outcomes, recurrence, disease-free survival, and resection margins. RESULTS: Overall, 37 comparative non-randomised studies with 4863 patients were included, of which 24% PHC and 76% IHC. In 21 studies, propensity score matching was performed. In total, 2106 laparoscopic, 75 robotic, and 2662 open procedures were analysed. The conversion rate was median 11.5% [IQR 10.0-12.5]. MILS probably resulted in reduced rates of major morbidity, 13.3% vs 18.8% (OR 0.75, 95%CI 0.62-0.90), mortality, 3.0% vs 4.5% (OR 0.69, 95%CI 0.49-0.97), and shorter hospital stay, 8.0 vs 10.9 days (MD -2.1, 95%CI -2.8 - -1.5). MILS resulted in higher rate of R0 resections in PSM cohort, 90.4% vs 81.4%, (OR 1.40, 95%CI 1.13-1.74) and better 3-year disease-free survival rate (49.9% vs 38.5%, HR3-year 3.2, 95%CI 3.1-3.3). In the subgroup of 1180 patients in whom a hepatico-jejunostomy was performed (498 laparoscopic, 65 robotic, 617 open) MILS remained associated with reduced major morbidity, 20.9% vs 27.6% (OR 0.88, 95%CI 0.64-1.21) and resulted in better mortality, 4.2% vs 4.9% (OR 0.51, 95%CI 0.30-0.86), as compared to the open approach. Overall, the rate of biliary leakage was likely similar, 10.6% versus 11.7% (OR 0.83, 95%CI 0.52-0.77). CONCLUSION: This systematic review of non-randomised comparative studies suggests that MILS for PHC and IHC may result in a similar safety profile with benefits in patient recovery and oncological outcomes as compared to OLS. Prospective comparative studies, especially including robotic MILS, are warranted.
引用
- de Hondt J, Zwart MJW, Uijterwijk BA, et al. Minimally invasive liver surgery for perihilar and intrahepatic cholangiocarcinoma: systematic review and meta-analysis of comparative studies. Surg Endosc. 2025. PMID: 40931102. doi:10.1007/s00464-025-11900-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。